Boosting a Natural Brain Cannabinoid Delayed Seizure Development in Mice | Research

The takeaway

Blocking the enzyme that breaks down the endocannabinoid 2-AG slowed the progression of seizure development in a mouse model of epilepsy, but had minimal effect once seizures were established.

Readers interested in how the endocannabinoid system relates to epilepsy and seizure prevention.

Seizure development was significantly delayed (p=0.0066) by boosting 2-AG levels

What the researchers found

Researchers tested whether increasing levels of the brain's own cannabinoid 2-AG, by blocking the enzyme MAGL that normally breaks it down, could slow epilepsy development in mice.

Using JZL184, a MAGL inhibitor, they found it significantly delayed the progression from mild to generalized seizures in the kindling model of temporal lobe epilepsy. Seizure duration and afterdischarge duration were both reduced during the kindling process.

However, once mice were fully kindled (seizures fully established), JZL184 had only modest effects. The anti-seizure effects disappeared in mice genetically engineered to lack CB1 receptors in forebrain neurons, confirming the drug worked through the cannabinoid system.

Why it matters

Most epilepsy drugs manage existing seizures but do not prevent epilepsy from developing. This study suggests that boosting endocannabinoid signaling could potentially slow or prevent epilepsy development, which would represent a fundamentally different treatment approach.

The numbers in context

JZL184 at 8 mg/kg significantly delayed generalized seizure development (p=0.0066). Seizure duration was reduced (p<0.0001). Afterdischarge duration decreased (p<0.001). Effects were absent in CB1 receptor knockout mice.

How the study worked

Mice received JZL184 (8 mg/kg) or vehicle before kindling stimulations. Researchers tracked seizure severity scores, seizure duration, and afterdischarge duration. Conditional CB1 receptor knockout mice were used to confirm mechanism. The kindling model progressively induces seizures through repeated electrical stimulation.

What this study cannot tell us

The kindling model is one of several epilepsy models and may not fully represent human epilepsy. Results from mice do not directly translate to humans. The drug showed limited benefit once seizures were already established, and long-term effects were not studied.

How to read the evidence

This is an animal study in mice. While the results are compelling, they require replication and eventual testing in humans before clinical relevance can be determined.

When this study was published

Published in 2015. Research on endocannabinoid-based approaches to epilepsy has continued to advance, particularly with the approval of CBD-based medications.

The bigger picture

This study adds to growing evidence that the endocannabinoid system plays a role in seizure regulation. Rather than directly activating cannabinoid receptors (like THC does), boosting naturally produced cannabinoids at sites of excessive brain activity could offer a more targeted approach with potentially fewer side effects.

Questions still open

Could MAGL inhibitors prevent epilepsy development in humans after a brain injury or other trigger? Would combining MAGL inhibition with existing anti-seizure medications improve outcomes?

Common questions

Is this the same thing as using CBD for seizures?

No. This study targeted a different part of the endocannabinoid system by blocking the enzyme that breaks down 2-AG, rather than using CBD or THC directly. CBD works through multiple mechanisms that are distinct from MAGL inhibition.

Could this approach prevent epilepsy rather than just treat it?

That is one implication of the findings. The drug slowed seizure development but had minimal effect on established seizures, which suggests potential for preventive rather than acute treatment. However, this has only been shown in mice.

Read the original research

Inhibition of monoacylglycerol lipase mediates a cannabinoid 1-receptor dependent delay of kindling progression in mice.

Neurobiology of disease, 77, 238-45

View on PubMed ↗Publisher’s paper ↗

Citation

von Rüden, E L; Bogdanovic, R M; Wotjak, C T; Potschka, H. (2015). Inhibition of monoacylglycerol lipase mediates a cannabinoid 1-receptor dependent delay of kindling progression in mice.. Neurobiology of disease, 77, 238-45. https://doi.org/10.1016/j.nbd.2015.03.016